|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spiro SG and Silvestri GA: One hundred
years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yano T, Haro A, Shikada Y, Maruyama R and
Maehara Y: Non-Small cell lung cancer in never smokers as a
representative ‘non-smoking-associated lung cancer’: Epidemiology
and clinical features. Int J Clin Oncol. 16:287–293. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bird A: DNA methylation patterns and
epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jankowska AM, Millward CL and Caldwell CW:
The potential of DNA modifications as biomarkers and therapeutic
targets in oncology. Expert Rev Mol Diagn. 15:1325–1337. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu F and Zhang HT: DNA methylation and
nonsmall cell lung cancer. Anat Rec (Hoboken). 294:1787–1795. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seok Y, Lee WK, Park JY and Kim DS: TGFBI
promoter methylation is associated with poor prognosis in lung
adenocarcinoma patients. Mol Cells. 42:161–165. 2019.PubMed/NCBI
|
|
8
|
Tessema M, Yingling CM, Liu Y, Tellez CS,
Van Neste L, Baylin SS and Belinsky SA: Genome-Wide unmasking of
epigenetically silenced genes in lung adenocarcinoma from smokers
and never smokers. Carcinogenesis. 35:1248–1257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shaulian E and Karin M: AP-1 as a
regulator of cell life and death. Nat Cell Biol. 4:E131–E136. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ting CH, Chen YC, Wu CJ and Chen JY:
Targeting FOSB with a cationic antimicrobial peptide, TP4, for
treatment of triple-negative breast cancer. Oncotarget.
7:40329–40347. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Na HH, Noh HJ, Cheong HM, Kang Y and Kim
KC: SETDB1 mediated FosB expression increasing the cell
proliferation rate during anticancer drug therapy. BMP Rep.
49:238–243. 2016. View Article : Google Scholar
|
|
12
|
Milde-Langosch K: The fos family of
transcription factors and their role in tumorigenesis. Eur J
Cancer. 41:2449–2461. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barrett CS, Millena AC and Khan SA: TGF-β
effects on prostate cancer cell migration and invasion require
FosB. Prostate. 77:72–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cervantes-Madrid DL, Nagi S and Asting
Gustafsson A: FosB transcription factor regulates COX-2 expression
in colorectal cancer cells without affecting PGE2 expression. Oncol
Lett. 13:1411–1416. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shahzad MMK, Arevalo JM, Armaiz-Pena GN,
Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB,
Bottsford-Miller J, et al: Stress effects on FosB- and
interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J
Biol Chem. 285:35462–35470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Renaud SJ, Kubota K, Rumi MA and Soares
MJ: The FOS transcription factor family differentially controls
trophoblast migration and invasion. J Biol Chem. 289:5025–5039.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rowther FB, Wei W, Dawson TP, Ashton A,
Singh A, Madiesse-Timchou MP, Thomas DG, Darling JL and Warr T:
Cyclic nucleotide phosphodiesterase-1C (PDE1C) drives cell
proliferation, migration and invasion in glioblastoma multiform
cells in vitro. Mol Carcinog. 55:268–279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang C, Jiang Y, Shao W, Shi W, Gao X, Qin
W, Jiang T, Wang F and Feng S: Abnormal expression of FOSB
correlates with tumor progression and poor survival in patients
with gastric cancer. Int J Oncol. 49:1489–1496. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JH, Lee JY, Lee KT, Lee JK, Lee KH,
Jang KT, Heo JS, Choi SH and Rhee JC: RGS16 and fosB underexpressed
in pancreatic cancer with lymph node metastasis promote tumor
progression. Tumour Biol. 31:541–548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Milde-Langosch K, Kappes H, Riethdorf S,
Loning T and Bamberger AM: FosB is highly expressed in normal
mammary epithelia, but down-regulated in poorly differentiated
breast carcinomas. Breast Cancer Res Treat. 77:265–275. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang LQ, Zhao LH and Qiao YZ:
Identification of potential therapeutic targets for lung cancer by
bioinformatics analysis. Mol Med Rep. 13:1975–1982. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim DS, Lee WK and Park JY:
Hypermethylation of normal mucosa of esophagus-specific 1 is
associated with an unfavorable prognosis in patients with non-small
cell lung cancer. Oncol Lett. 16:2409–2415. 2018.PubMed/NCBI
|
|
23
|
Anier K, Malinovskaja K, Aonurm-Helm A,
Zharkovsky A and Kalda A: DNA methylation regulates cocaine-induced
behavioral sensitization in mice. Neuropsychopharmacol.
35:2450–2461. 2010. View Article : Google Scholar
|
|
24
|
Suzuki T, Yamashita S, Ushijima T, Takumi
S, Sano T, Michikawa T and Nohara K: Genome-Wide analysis of DNA
methylation changes induced by gestational arsenic exposure in
liver tumors. Cancer Sci. 104:1575–1585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen ZX and Riggs AD: DNA methylation and
demethylation in mammals. J Biol Chem. 286:18347–18353. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kulis M, Heath S, Bibikova M, Queiros AC,
Navarro A, Clot G, Martinez-Trillos A, Castellano G, Brun-Health I,
Pinyol M, et al: Epigenomic analysis detects widespread gene-body
DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet.
44:1236–1242. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang X, Han H, De Carvalho DD, Lay FD,
Jones PA and Liang G: Gene body methylation can alter gene
expression and is a therapeutic target in cancer. Cancer Cell.
26:577–590. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kulis M, Queiros AC, Beekman R and
Martin-Subero JI: Intragenic DNA methylation in transcriptional
regulation, normal differentiation and cancer. Biochim Biophys
Acta. 1829:1161–1174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee SM, Choi WY, Lee J and Kim YJ: The
regulatory mechanisms of intragenic DNA methylation. Epigenomics.
7:527–531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Esteller M: Dormant hypermethylated tumor
suppressor genes: Questions and answers. J Pathol. 205:172–180.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Milde-Langosch K, Roder H, Andritzky B,
Aslan B, Hemminger G, Brinkmann A, Bamberger CM, Loning T and
Bamberger AM: The role of the AP-1 transcription factors c-Fos,
FosB, Fra-1 and Fra-2 in the invasion process of mammary
carcinomas. Breast Cancer Res Treat. 86:139–152. 2004. View Article : Google Scholar : PubMed/NCBI
|
